First animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
List view / Grid view
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
Dr Laura Figulla is the CEO of mbiomics. Laura co-founded mbiomics which is dedicated to unlocking the true value of the microbiome by developing next-generation live biotherapeutics (LBPs). Throughout her career, Laura has combined her entrepreneurial spirit with her diverse academic background in business, economics, and medicine to build companies that…
The new organoids demonstrate a greater diversity of TECs in culture and are capable of maturing T cells.
Adult anxious behaviour in offspring may be related to the early life proinflammatory state caused by the absence of elevated XCL1.
In this episode, we discuss the current advantages and limitations of using organoids, as well as where the field is heading.
In animal studies, the new vaccine construct outperformed another PNAG-vaccine delivery system currently in human trials.
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
Epigenetic data assessing the effects of smoking on DNA methylation could serve as biomarkers of exposure effects.
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
In mouse models, the differences between oocytes collected by natural or stimulated approaches were investigated.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.